Fortrea Holdings (FTRE) Depreciation & Amortization (CF) (2022 - 2026)
Fortrea Holdings (FTRE) reported Depreciation & Amortization (CF) of $19.8 million for Q1 2026, up 1.54% on a YoY basis from $19.5 million in Q1 2025, and up 2.59% quarter-over-quarter from $19.3 million in Q4 2025.
Fortrea Holdings (FTRE) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Depreciation & Amortization (CF) for 5 years, with the latest figure at $19.8 million in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 1.54% year-over-year to $19.8 million; the trailing twelve-month figure through Mar 2026 stood at $78.3 million (down 5.55% YoY), and the FY2025 full-year result was $78.0 million, down 10.24% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $19.8 million, up from $19.3 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $25.1 million in Q2 2023, with the low at $19.3 million in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $22.0 million across 5 years, with a median of $22.0 million in 2022.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) grew 8.37% — and 2025, when it declined 17.02%.
- Fortrea Holdings' Depreciation & Amortization (CF) stood at $23.9 million in 2022, then increased by 2.09% to $24.4 million in 2023, then slipped by 14.75% to $20.8 million in 2024, then slipped by 7.21% to $19.3 million in 2025, then increased by 2.59% to $19.8 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $19.8 million (Q1 2026), $19.3 million (Q4 2025), and $19.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | 19.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.80 Mn |
| Mar 31, 2026 | 19.80 Mn |
| Dec 31, 2025 | 19.30 Mn |
| Dec 31, 2025 | 19.30 Mn |
| Sep 30, 2025 | 19.60 Mn |
| Sep 30, 2025 | 19.60 Mn |
| Jun 30, 2025 | 19.60 Mn |
| Jun 30, 2025 | 19.60 Mn |
| Mar 31, 2025 | 19.50 Mn |
| Mar 31, 2025 | 19.50 Mn |
| Dec 31, 2024 | 20.80 Mn |
| Dec 31, 2024 | 20.80 Mn |
| Sep 30, 2024 | 21.20 Mn |
| Sep 30, 2024 | 21.20 Mn |
| Jun 30, 2024 | 21.40 Mn |
| Jun 30, 2024 | 21.40 Mn |
| Mar 31, 2024 | 23.50 Mn |
| Mar 31, 2024 | 23.50 Mn |
| Dec 31, 2023 | 24.40 Mn |
| Dec 31, 2023 | 24.40 Mn |